Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biocept Inc (BIOC)

Biocept Inc (BIOC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,125
  • Shares Outstanding, K 92,673
  • Annual Sales, $ 3,250 K
  • Annual Income, $ -24,570 K
  • 60-Month Beta -0.89
  • Price/Sales 5.13
  • Price/Cash Flow N/A
  • Price/Book 0.92
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.67
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/13/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.42
  • Growth Rate Est. (year over year) +41,380.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2112 +33.48%
on 03/17/20
0.7890 -64.27%
on 02/28/20
-0.0081 (-2.79%)
since 02/27/20
3-Month
0.2112 +33.48%
on 03/17/20
0.7890 -64.27%
on 02/28/20
+0.0317 (+12.67%)
since 12/27/19
52-Week
0.2112 +33.48%
on 03/17/20
2.1100 -86.64%
on 05/21/19
-0.8581 (-75.27%)
since 03/27/19

Most Recent Stories

More News
Biocept Enters into Laboratory Services Agreement with Second California-Based Independent Physician Association

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.2819 (-7.97%)
Biocept Reports 2019 Fourth Quarter and Full Year Financial Results

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports...

BIOC : 0.2819 (-7.97%)
Biocept, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 25, 2020 / Biocept, Inc. (NASDAQ:BIOC) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 25, 2020 at 4:30 PM Eastern...

BIOC : 0.2819 (-7.97%)
Biocept, Inc. Discusses Highlights for 2019, Recent News and What to Look Out For in Q2 2020 in New SNNLive Video Interview on SNN Network

LOS ANGELES, CA / ACCESSWIRE / March 18, 2020 / , The Official MicroCap News Source™, today published an SNNLive Video Interview with Mike Nall, CEO of Biocept, Inc. (NASDAQ:BIOC), a leading commercial...

BIOC : 0.2819 (-7.97%)
Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.2819 (-7.97%)
Newly Published Data in Journal of Clinical Pathology Provides Clinical Validation for Biocept's Target Selector(TM) qPCR Assay to Identify Cancer-Associated Mutations

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.2819 (-7.97%)
Biocept Announces Pricing of $6.6 Million Registered Direct Offering Priced At-The-Market

Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes...

BIOC : 0.2819 (-7.97%)
Biocept Announces Pricing of $9.2 Million Registered Direct Offering Priced At-The-Market

Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes...

BIOC : 0.2819 (-7.97%)
Biocept Appoints Cory J. Dunn Senior Vice President of Commercial Operations

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.2819 (-7.97%)
Biocept Enters into Laboratory Services Agreement with California-Based Independent Physician Association

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with...

BIOC : 0.2819 (-7.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade BIOC with:

Business Summary

Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept,...

See More

Key Turning Points

2nd Resistance Point 0.3135
1st Resistance Point 0.2977
Last Price 0.2819
1st Support Level 0.2678
2nd Support Level 0.2537

See More

52-Week High 2.1100
Fibonacci 61.8% 1.3847
Fibonacci 50% 1.1606
Fibonacci 38.2% 0.9365
Last Price 0.2819
52-Week Low 0.2112

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar